---

$1.45

+0.0250 ( +1.76% ) 226.1K

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-10-01	Buy	200000.00	Oxford Science Enterprises plc
2025-09-30	Buy	9375000.00	RA CAPITAL MANAGEMENT, L.P.
2025-06-02	Buy	8375.00	STRECK PAUL
2024-07-26	Sale	-201.00	Mellion Michelle L
2024-07-19	Sale	-12625.00	Mellion Michelle L
2024-07-16	Sale	-3288.00	Mellion Michelle L
2024-07-03	Sale	-875.00	Mellion Michelle L
2023-12-05	Buy	1694.00	McArthur James G
2023-11-14	Sale	-22686.00	Mayer Howard